<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00872586</url>
  </required_header>
  <id_info>
    <org_study_id>SS-866 CMB/01</org_study_id>
    <nct_id>NCT00872586</nct_id>
  </id_info>
  <brief_title>Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension</brief_title>
  <official_title>A Randomized, Double-blind, Double-dummy, Multicenter Clinical Trial to Evaluate the Additional Efficacy and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension, Who Fail to Attain the Blood Pressure Goals With Olmesartan Medoxomil 20mg Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Sankyo Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the additional efficacy and safety of olmesartan
      medoxomil/hydrochlorothiazide in the treatment of Chinese patients with mild to moderate
      essential hypertension, who fail to attain the blood pressure goals with olmesartan medoxomil
      monotherapy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change of trough seated diastolic blood pressure from baseline to Week 12 between the two treatment groups.</measure>
    <time_frame>Baseline to12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The mean change of trough seated systolic blood pressure from Week 5 to Week 12 between the two treatment groups</measure>
    <time_frame>8 weeks (week 5 to week 12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change of trough seated diastolic blood pressure and seated systolic blood pressure from Week 5 to Week 9 between the two treatment groups</measure>
    <time_frame>5 weeks (Week 5 to week 9)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The response rate in the two treatment groups from baseline to Week 9</measure>
    <time_frame>Baseline to 9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The response rate in the two treatment groups from baseline to Week 12</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">304</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olmesartan medoxomil and hydrochlorothiazide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>olmesartan medoxomil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olmesartan medoxomil + hydrochlorothiazide</intervention_name>
    <description>olmesartan medoxomil 20mg oral tablets, once daily for 4 weeks then olmesartan medoxomil 20mg oral tablets + hydrochlorothiazide 12.5 mg oral tablets, once daily for up to 8 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olmesartan medoxomil</intervention_name>
    <description>olmesartan medoxomil 20mg oral tablets, once daily for 4 weeks then olmesartan medoxomil 40mg oral tablets, once daily for up to 8 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At Visit 3, mean seated diastolic blood pressure (SeDBP) ≥ 95 mmHg and &lt; 110 mmHg, AND
             mean seated systolic blood pressure (SeSBP) ≥140 mmHg and &lt; 180 mmHg

          -  At Visit 4, mean SeDBP ≥ 90 mmH

          -  No significant disorder in blood, kidney, liver, cardiovascular system or
             endocrinology system

        Exclusion Criteria:

          -  Patients with known or suspect secondary hypertension

          -  Unstable angina

          -  History of acute myocardial infarct, or PTCA or surgical cardiac procedures 3 months
             before entry into this study

          -  Prior or current congestive heart failure (NYHA grade III or IV), hypertrophic
             obstructive cardiomyopathy, valvular disease or rheumatic heart disease

          -  Arrhythmia of clinical significance

          -  Bilateral renal artery stenosis, isolated renal artery stenosis, post kidney
             transplantation

          -  Acute glomerular nephritis

          -  Gout sufferers, even with the normal serum uric acid at entry

          -  Retinal hemorrhage /exudate

          -  Type 1 diabetes mellitus

          -  Uncontrolled type 2 diabetes mellitus

          -  Hypovolemia

          -  Patients with autoimmune disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naotaka Ikegami, VP</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Sankyo Pharmaceuticals Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guang Zhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hang Zhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2009</study_first_submitted>
  <study_first_submitted_qc>March 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2009</study_first_posted>
  <last_update_submitted>September 28, 2010</last_update_submitted>
  <last_update_submitted_qc>September 28, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2010</last_update_posted>
  <responsible_party>
    <name_title>Naotaka Ikegami, Vice President</name_title>
    <organization>Shanghai Sankyo Pharmaceuticals, Co., Ltd.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

